Resources

The UK’s Cell and Gene Therapy Catapult has published new insights into the advancement of the UK’s cell and gene therapy industry in its 2024 ATMP Clinical Trials Database.

Scancell Holdings plc (AIM: SCLP), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, has achieved significant clinical and commercial milestones in its ModiFY study.

J.P. Morgan Healthcare Conference 2025: Genomics announces Dr. Jose-Carlos Gutiérrez-Ramos as new board member to accelerate global expansion and life sciences R&D growth.

The global life science investment and media community are heading to the JPM Healthcare Conference next week and we’ll be keeping an eye on announcements and grants that impact our industry.

David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics.

New legislation was laid in Parliament last Thursday to modernise the regulation of clinical trials in the UK.

Patients, the NHS and the Life Sciences sector set to benefit from new clinical trials framework being laid in parliament today.

Momentum Pharma breaks ground by becoming the first organization to receive new certification assessing highest industry standards.

Relation Therapeutics announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

As we engage as an Association in the development of the life science sector plan, the 10 year NHS plan and the UK’s industrial strategy this winter, this week I’ve been reflecting on what recent NHS announcements on adoption of innovation tell us.

Microbiotica announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.

Rinri Therapeutics, which is focused on transforming hearing loss treatment with regenerative cell therapy, announces that the novel surgical procedure to be used for regenerative cell delivery in its first-in-human trial has been published in the prestigious journal Nature Scientific Reports.

NRG Therapeutics, Ltd has achieved a key milestone with the nomination of its first development candidate, NRG5051 and has been awarded a $5M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

In response to the global rise in demand for innovative therapies, the development and production of novel biopharmaceuticals continue to expand.

Astex Pharmaceuticals announced today that it will make five key data presentations at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, 23rd-25th October 2024, Barcelona, Spain.

Landmark studies represent the largest investigational trials to be conducted to date for cannabinoids as a treatment for refractory epilepsy.

Ikarovec’s seed round extension raises funds to continue advanced pre-clinical trials of novel gene therapies to treat blindness and major chronic eye disease.

Today marks a pivotal moment for our Association as a key strategic objective has been realised: the new government has placed growth at the centre of its agenda, with life sciences positioned as a cornerstone of that plan.